Orpha Labs AG Announces the Initiation of a Phase III Trial

BAAR, Switzerland, Feb. 23, 2022 /PRNewswire/ -- Orpha Labs AG, a clinical-stage biopharmaceutical company focused on diseases with unmet needs, today announced the initiation of the Phase III

Related Keywords

United States , Switzerland , Amos Etzioni , Kostenloser Wertpapierhandel , Bugra Basat , Drug Administration , Leukocyte Adhesion Deficiency Type , Orpha Labs , Alp Bugra Basat , Chief Executive Officer , Professor Emeritus , Rappaport Faculty , Scientific Advisory Board , Rare Pediatric Disease Designation , New Drug Application , Priority Review Voucher , Orphan Drug Designation , Current Good Manufacturing Practice , Fucose Transporter , Orpha , Labs , Nnounces , Initiation , Hase , Trial , Valuating , Treatment , Leukocyte , Adhesion , Deficiency , Type ,